Tempest Therapeutics, Inc. TPST
Set alert
At close · Oct 30
After hours · Oct 30, 7:11 PM ET
- YTD
- -82.74%
- 1 year
- -95.29%
- Open
- 0.5333
- Prev close
- 0.5332
- Mkt cap
- 9.91M
- Vol
- 163.47K
- Avg vol
- 2.58M
- EPS
- -3.93
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4902
- High
- 0.5466
- Forward P/E
- -0.61
- Beta
- -2.78
- Short ratio
- 0.39
- Inst. own
- 23.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.95482
- 200-d avg
- 2.12
- 1y target
- 18.75
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
-
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
-
1 month ago benzinga.com
Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock
Up to 9,534,164 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus, referred to as the selling stockholders,…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07%…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday's after-market session. The market value of their outstanding shares is at $8.3 million. Alaunos…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
1 month ago benzinga.com
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Shares of Tempest Therapeutics Inc (NASDAQ: TPST) are trading sharply higher Wednesday morning as investors respond positively to a strategic agreement expanding the company's next-generation cell…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
1 month ago benzinga.com
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
1 month ago benzinga.com
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why
Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreement expanding its in vivo CAR-T pipeline.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
-
1 month ago benzinga.com
Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share
Tempest Therapeutics, Inc. (Nasdaq: TPST) (the "Company"), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease,…
-
2 months ago benzinga.com
Tempest Therapeutics Secures $50M Equity Purchase Agreement With Lincoln Park Capital
On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the
-
2 months ago benzinga.com
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses…
-
3 months ago benzinga.com
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell…
-
3 months ago benzinga.com
Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS Patients
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. Mobile-health Network…
-
4 months ago benzinga.com
Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm
-
5 months ago benzinga.com
Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses…
-
6 months ago benzinga.com
Tempest Therapeutics To Present Most Recent Clinical Data From Lead Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy Product Candidate, TPST-2003, At ISCT Scientific Annual Meeting
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure…
-
6 months ago benzinga.com
Tempest Therapeutics Reaches Milestone In TPST-2003 Manufacturing Process
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma ("rrMM") through a parallel…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
7 months ago benzinga.com
Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(3.52) by 82.39 percent. This is a 87.77 percent increase over losses…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
7 months ago benzinga.com
Tempest Therapeutics Announces Up To $6M Private Placement; Warrants Will Have Exercise Price Of $2.16/Share
Tempest Therapeutics has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to…
-
7 months ago benzinga.com
Tempest Therapeutics Selects Cincinnati Children's AGCTC As Lead Contract Development And Manufacturing Partner To Conduct Formal Technology Transfer Of TPST-2003 For Treatment Of rrMM
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned…
-
8 months ago benzinga.com
Tempest Therapeutics Announces Clinical Data From Ongoing REDEEM-1 Phase 1/2a Trial Evaluating TPST-2003, CD19/BCMA Dual-Targeting CAR-T Therapy
100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
9 months ago benzinga.com
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target
HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
11 months ago benzinga.com
Tempest Therapeutics Announces ~$4.25M Offering Of 1.2M Common Stock, 1.2M Warrants At $3.625/Share
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 months ago benzinga.com
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 months ago benzinga.com
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast
11 months ago benzinga.com
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.
-
11 months ago benzinga.com
Tempest Announces Matt Angel To Assume Role Of President And CEO; Stephen Brady To Assume Role Of Chairman Of The Board Of Directors Upon Closing Of The Acquisition
Matt Angel, Ph.D.Dr. Matt Angel is an experienced biotechnology executive with expertise in leading lean cell therapy companies. Dr. Angel led Brooklyn Immunotherapeutics (NASDAQ:BTX) as CEO from…
-
11 months ago benzinga.com
UPDATE: Tempest To Acquire Factor's Dual-CAR T Programs In All-Stock Deal, Issuing 8,268,495 Shares; Stockholders Will Be Entitled To Receive 1 Common Stock Warrant For Every Share Of Common Stock Held And Outstanding At A Date Immediately Prior To The Closing; Warrants Will Be Immediately Exercisable With An Initial Exercise Price Equal To $18.48 And Will Expire 5-Years From The Issuance Date
Tempest will issue 8,268,495 shares of its common stock, par value $0.001 per share ("Common Stock"), to an affiliate of Factor, equal to 65% of the outstanding shares of Common Stock, inclusive of…
-
11 months ago benzinga.com
Tempest Therapeutics Signs Agreements To Acquire Certain Dual-Targeting Chimeric Antigen Receptor-T Programs From Factor Bioscience
Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "the Company"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today…
-
12 months ago benzinga.com
Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(3.27) by 75.84 percent. This is a 85.15 percent increase over losses…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session